Two-year observation of a randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplantation

Chinese Medical Sciences Journal

Volumn 23, Issue 4, 2008, Pages 244-248

  Zhu, Qing Guo ^a   Zhao, Ya Kun ^a   Liu, Wei ^a   Luo, Hui ^a   Qiu, Yu ^a   Gao, Zhi Zhong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Mycophenolate mofetil; Renal transplantation; Steroid; Tacrolimus

Indexed keywords

INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

ARTICLE; CADAVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; PERIANAL ABSCESS; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; URINARY TRACT INFECTION;

EID: 58849102684     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1001-9294(09)60047-X     Document Type: Article

References (13)

1. Hricik DE. Steroid withdrawal in renal transplant recipients: pro point of view. Transplant Proc 1998; 30:1380-2.
2. Rama I, Cruzado JM, Gil-Vernet S, et al. Steroids can be safely withdrawn from cyclosporine and mycophenolate mofetil-treated renal allograft recipients: long-term results. Transplantation 2005; 80:164-8.
3. Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation 2000; 69:875-80.
4. Kramer BK, Kruger B, Mack M, et al. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens. Transplant Proc 2005; 37:1789-91.
5. Prima V, Depoix C, Masselot B, et al. Alteration of the glucocorticoid receptor subcellular localization by non steroidal compounds. J Steroid Biochem Mol Biol 2000; 72:1-12.
6. Hutchinson IV, Bagnall W, Bryce P, et al. Differences in the mode of action of cyclosporine and FK 506. Transplant Proc 1998; 30:959-60.
7. Loucaidou M, Borrows R, Cairns T, et al. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe. Transplant Proc 2005; 37:1795-6.
8. Abramowicz D, Vanrenterghem Y, Squifflet JP, et al. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Clin Transplant 2005; 19:475-82.
9. Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006; 81:832-9.
10. Balal M, Demir E, Paydas S, et al. Uncommon side effect of MMF in renal transplant recipients. Ren Fail 2005; 27:591-4.
11. Kaplan B, Meier-Kriesche HU, Vaghela M, et al. Withdrawal of mycophenolate mofetil in stable renal transplant recipients. Transplantation 2000; 69:1726-8.
12. ter Meulen CG, Gregoor PJ, Weimar W, et al. Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone. Transpl Int 2001; 14:99-102.
13. Squifflet JP, Vanrenterghem Y, van Hooff JP, et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34:1584-6.